Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.37 |
| ▸ | LSS | P48449 | 5/20 | 0.37 |
| ▸ | TP53 | P04637 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 4/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6400289 | 0.91 | MAPT (0.41) | MAPTLSSTP53RORCLMNA | |
| SCHEMBL5635668 | 0.91 | HRH3 (0.41) | MAPTLSSTP53RORCHRH3 | |
| SCHEMBL6403927 | 0.89 | MAPT (0.40) | MAPTLSSTP53LMNAPOLB | |
| SCHEMBL6399634 | 0.88 | LSS (0.38) | MAPTLSSTP53RORCLMNA | |
| SCHEMBL6400906 | 0.87 | LSS (0.37) | MAPTLSSTP53RORCLMNA | |
| SCHEMBL5638296 | 0.87 | MAPT (0.47) | MAPTLSSTP53LMNAPOLB | |
| SCHEMBL6403814 | 0.87 | NLRP3 (0.41) | MAPTLSSTP53ALDH1A1POLB | |
| SCHEMBL6400152 | 0.86 | LSS (0.44) | MAPTLSSTP53HRH3 | |
| SCHEMBL6400371 | 0.86 | LSS (0.44) | MAPTLSSTP53HRH3 | |
| SCHEMBL6430242 | 0.86 | LSS (0.49) | MAPTLSSTP53HRH3NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187390-A1 | Bicyclic heteroaryl derivatives | HAVCR2, MAVS, ZC3HAV1 | MAPT 2748/4885LSS 65/4885TP53 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.